Featured Publications
Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype
Tyagi T, Ahmad S, Gupta N, Sahu A, Ahmad Y, Nair V, Chatterjee T, Bajaj N, Sengupta S, Ganju L, Singh SB, Ashraf MZ. Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. Blood 2013, 123: 1250-1260. PMID: 24297866, DOI: 10.1182/blood-2013-05-501924.Peer-Reviewed Original ResearchConceptsCalpain activityPlatelet reactivityProthrombotic phenotypeThrombus formationSoluble P-selectin levelsIncidence of thrombosisP-selectin levelsProthrombotic rolePlatelet hyperreactivitySolid tumorsVivo modelSmall subunit 1ThrombosisPathological conditionsAltered expressionHypoxic conditionsHypoxic environmentPlatelet proteinsHypoxiaExtreme altitudePresent studyCalpain functionPlateletsSubunit 1Phenotype
2020
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI, Halene S, Martin KA, Chun HJ, Hwa J. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews Cardiology 2020, 18: 194-209. PMID: 33214651, PMCID: PMC7675396, DOI: 10.1038/s41569-020-00469-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdministration, InhalationAnticoagulantsBlood Coagulation DisordersBlood Platelet DisordersCOVID-19COVID-19 Drug TreatmentEndothelium-Dependent Relaxing FactorsEndothelium, VascularEpoprostenolHeart Disease Risk FactorsHumansIloprostInflammationNitric OxidePlatelet Aggregation InhibitorsSARS-CoV-2Systemic Inflammatory Response SyndromeThrombosisThrombotic MicroangiopathiesVascular DiseasesVasodilator AgentsVenous ThromboembolismConceptsCardiovascular risk factorsRisk factorsCOVID-19Severe acute respiratory syndrome coronavirus 2Pre-existing cardiovascular diseaseAcute respiratory syndrome coronavirus 2Traditional cardiovascular risk factorsAcute respiratory distress syndromeRespiratory syndrome coronavirus 2Respiratory distress syndromeManagement of patientsSyndrome coronavirus 2COVID-19 pathologyCoronavirus disease 2019Potential therapeutic strategyCytokine stormEndothelial dysfunctionThrombotic complicationsDistress syndromeExcessive inflammationCoronavirus 2Severe outcomesAdvanced ageCardiovascular diseaseDisease 2019
2019
Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability
Scanlon VM, Teixeira AM, Tyagi T, Zou S, Zhang PX, Booth CJ, Kowalska MA, Bao J, Hwa J, Hayes V, Marks MS, Poncz M, Krause DS. Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability. Thrombosis And Haemostasis 2019, 119: 744-757. PMID: 30861547, PMCID: PMC6599679, DOI: 10.1055/s-0039-1679908.Peer-Reviewed Original ResearchConceptsConditional knockout miceKnockout micePlatelet aggregationE-cadherinClot stabilityClot stabilizationSynthase kinase 3β activationAntibody-mediated platelet depletionVivo injury modelsNull plateletsPlatelet productionWild-type miceTail bleeding timeAkt/GSK3βMurine platelet aggregationKnockout mouse modelPlatelet dysfunctionFibrin depositionInjury modelPlatelet depletionPrimary human plateletsBleeding timeMouse modelPlatelet numberE-cadherin antibody
2017
MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis
Sahu A, Jha P, Prabhakar A, Singh H, Gupta N, Chatterjee T, Tyagi T, Sharma S, Kumari B, Singh S, Nair V, Goel S, Ashraf M. MicroRNA-145 Impedes Thrombus Formation via Targeting Tissue Factor in Venous Thrombosis. EBioMedicine 2017, 26: 175-186. PMID: 29217135, PMCID: PMC5832640, DOI: 10.1016/j.ebiom.2017.11.022.Peer-Reviewed Original ResearchConceptsMiR-145 levelsTissue factorVenous thromboembolismMiR-145Thrombus formationTF levelsTargeting tissue factorPromising therapeutic strategyCardiovascular complicationsThrombus loadVenous thrombosisCoagulation variablesPreclinical findingsTherapeutic strategiesVT patientsTF expressionInverse correlationKey moleculesPatientsVivo experimentsUndescribed roleTarget genesVTThromboembolismLevels
2015
Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action
Rashid Q, Abid M, Gupta N, Tyagi T, Ashraf M, Jairajpuri M. Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action. BioMed Research International 2015, 2015: 630482. PMID: 25866798, PMCID: PMC4381846, DOI: 10.1155/2015/630482.Peer-Reviewed Original ResearchConceptsFavorable safety profileNovel anticoagulant agentsForm of heparinAnticoagulant administrationSafety profileAntithrombotic agentsAnticoagulant agentsAnticoagulant factorsHemostatic balanceAntithrombotic potentialLow doseAntiplatelet mechanismFibrinolytic systemPlatelet aggregationThrombotic ratsFirst lineHeparinCoagulation timeRatsBlood plasmaNovel compoundsThromboembolismComplicationsAnticoagulantsTherapy